Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT03148093 Terminated - Clinical trials for Metastatic Colorectal Cancer

The CHOICE Registry

Start date: June 30, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The CHOICE Registry will describe real-world treatment patterns and physician and patient (and caregiver)-reported outcomes associated with patients who have progressed beyond 2nd line metastatic colorectal cancer.

NCT ID: NCT03035253 Terminated - Clinical trials for Metastatic Colorectal Cancer

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Start date: December 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread. The study is sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the Sponsor.

NCT ID: NCT02851004 Terminated - Clinical trials for Metastatic Colorectal Cancer

Special Combination of BBI608 and Pembrolizumab

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

the efficacy and safety of BBI608 in combination with pembrolizumab

NCT ID: NCT02654639 Terminated - Clinical trials for Metastatic Colorectal Cancer

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

ALEXANDRIA
Start date: February 2016
Phase: Phase 2
Study type: Interventional

Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC

NCT ID: NCT02611661 Terminated - Clinical trials for Metastatic Colorectal Cancer

Local Ablative Strategies After Endovascular Radioembolization

LASER
Start date: January 19, 2016
Phase: Phase 1
Study type: Interventional

The rationale for this design is initial utilization of a standard-of-care therapy for mCRC (radioembolization) with a dose-calculation algorithm that has been verified as predictive for treatment response. Prediction of treatment failure will enable the proposed subsequent locoregional therapies which were selected based on safety profiles and feasibility. While the goal of this study is assessing feasibility and safety of this approach, the end goal of improving overall patient outcomes by improved hepatic tumor control.

NCT ID: NCT02605044 Terminated - Clinical trials for Metastatic Colorectal Cancer

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Start date: January 2014
Phase: Phase 3
Study type: Interventional

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.

NCT ID: NCT02597075 Terminated - Clinical trials for Metastatic Colorectal Cancer

Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy

Start date: March 17, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether a structured physical activity program (PA) during palliative chemotherapy improves progression-free survival (PFS) and/or patient-reported outcomes (ESAS-r) in patients with metastatic colorectal cancer.

NCT ID: NCT02568046 Terminated - Clinical trials for Metastatic Colorectal Cancer

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Start date: March 15, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).

NCT ID: NCT02511756 Terminated - Clinical trials for Metastatic Colorectal Cancer

Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

AVA-CTP
Start date: July 2015
Phase: N/A
Study type: Interventional

The primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by CTP as a predictive marker for efficacy measured by progression-free survival (PFS) in mCRC patients under first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy

NCT ID: NCT02448810 Terminated - Clinical trials for Metastatic Colorectal Cancer

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Start date: June 15, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy between BAX69 in combination with 5-FU/LV for subjects with KRAS or NRAS mutated tumor (mt) or panitumumab, for subjects with KRAS and NRAS wild type tumor (wt) and standard of care (SoC) per investigator choice as third or fourth treatment line in subjects with progressive measurable metastatic colorectal cancer (mCRC).